Sensitivity of the systemic lupus erythematosus disease activity index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset Systemic Lupus Erythematosus

Arthritis and Rheumatism

Volumn 42, Issue 7, 1999, Pages 1354-1360

  Brunner, Hermine I ^a   Feldman, Brian M ^a   Bombardier, C ^a   Silverman, Earl D ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ADOLESCENT; ANALYTIC METHOD; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; KIDNEY BIOPSY; MALE; ONSET AGE; PRIORITY JOURNAL; SCORING SYSTEM; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED KINGDOM;

ADULT; BIOPSY; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; FEMALE; HEADACHE; HUMANS; HYPERTENSION; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; SEVERITY OF ILLNESS INDEX; VISUAL ACUITY;

EID: 0033508774     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199907)42:7<1354::AID-ANR8>3.0.CO;2-4     Document Type: Article

References (18)

1. Tucker LB, Menon S, Schaller J. Adult-and childhood-onset lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol 1995;34:866-72.
2. Hawker G, Gabriel S, Bombardier C. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol 1993;20:657-60.
3. Gladman D, Goldsmith C, Urowitz M. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994;21:1468-71.
4. Guzman J, Cardiel M, Arce-Salinas A. Measurement of disease activity in systemic lupus erythematosus: prospective validation of 3 clinical indices. J Rheumatol 1992;19:1551-8.
5. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
6. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
7. Hay E, Bacon P, Gordon C. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. QJM 1993;86:447-58.
8. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32: 1107-18.
9. National Heart, Lung and Blood Institute. Report of the second task force on blood pressure control in children. Pediatrics 1987; 79:1-20.
10. Stoll T, Stucki G, Malil J. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996;55:756-60.
11. Kazis L, Anderson J, Meenan R. Effect sizes for interpreting changes in health status. Med Care 1989;27:S178-89.
12. Liang MH. Evaluating measurement responsiveness. J Rheumatol 1995;22:1191-2.
13. Cohen J. Statistical power analysis for the behavioural sciences. New York: Academic Press; 1977.
14. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987;40:171-8.
15. Liang MH, Larson MG, Cullen KE, Schwartz JA. Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. Arthritis Rheum 1985;28:542-7.
16. Beaton D, Hogg-Johson S. Evaluating changes in health status: reliability and responsiveness of five generic health status measures in workers with musculoskeletal disorders. J Clin Epidemiol 1997;50:79-93.
17. Wright J, Young N. A comparison of different indices of responsiveness. J Clin Epidemiol 1997;50:239-46.
18. Abrahamowicz M, Fortin PR. The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rheumatol 1998;25: 277-84.